Literature DB >> 32855761

Bayesian flexible hierarchical skew heavy-tailed multivariate meta regression models for individual patient data with applications.

Sungduk Kim1, Ming-Hui Chen2, Joseph Ibrahim3, Arvind Shah4, Jianxin Lin4.   

Abstract

A flexible class of multivariate meta-regression models are proposed for Individual Patient Data (IPD). The methodology is well motivated from 26 pivotal Merck clinical trials that compare statins (cholesterol lowering drugs) in combination with ezetimibe and statins alone on treatment-naïve patients and those continuing on statins at baseline. The research goal is to jointly analyze the multivariate outcomes, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), and Triglycerides (TG). These three continuous outcome measures are correlated and shed much light on a subject's lipid status. The proposed multivariate meta-regression models allow for different skewness parameters and different degrees of freedom for the multivariate outcomes from different trials under a general class of skew t-distributions. The theoretical properties of the proposed models are examined and an efficient Markov chain Monte Carlo (MCMC) sampling algorithm is developed for carrying out Bayesian inference under the proposed multivariate meta-regression model. In addition, the Conditional Predictive Ordinates (CPOs) are computed via an efficient Monte Carlo method. Consequently, the logarithm of the pseudo marginal likelihood and Bayesian residuals are obtained for model comparison and assessment, respectively. A detailed analysis of the IPD meta data from the 26 Merck clinical trials is carried out to demonstrate the usefulness of the proposed methodology.

Entities:  

Keywords:  CPO Identity II; Collapsed Gibbs; Heterogeneity; Multi-dimensional random effects; Multiple trials; Outlying trials

Year:  2020        PMID: 32855761      PMCID: PMC7448754          DOI: 10.4310/sii.2020.v13.n4.a6

Source DB:  PubMed          Journal:  Stat Interface        ISSN: 1938-7989            Impact factor:   0.582


  18 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

Review 2.  Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials.

Authors:  Amir Kashani; Tamer Sallam; Swarna Bheemreddy; Douglas L Mann; Yun Wang; JoAnne M Foody
Journal:  Am J Cardiol       Date:  2008-04-09       Impact factor: 2.778

3.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

4.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Authors:  Deepak L Bhatt; P Gabriel Steg; Michael Miller; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Ralph T Doyle; Rebecca A Juliano; Lixia Jiao; Craig Granowitz; Jean-Claude Tardif; Christie M Ballantyne
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

5.  Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.

Authors:  L A Leiter; D J Betteridge; M Farnier; J R Guyton; J Lin; A Shah; A O Johnson-Levonas; P Brudi
Journal:  Diabetes Obes Metab       Date:  2011-07       Impact factor: 6.577

6.  Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data with Applications to Cancer Clinical Trials.

Authors:  Danjie Zhang; Ming-Hui Chen; Joseph G Ibrahim; Mark E Boye; Wei Shen
Journal:  J Comput Graph Stat       Date:  2017-02-16       Impact factor: 2.302

7.  Hypertriglyceridemia as a cardiovascular risk factor.

Authors:  M A Austin; J E Hokanson; K L Edwards
Journal:  Am J Cardiol       Date:  1998-02-26       Impact factor: 2.778

8.  Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs.

Authors:  Sungduk Kim; Ming-Hui Chen; Joseph G Ibrahim; Arvind K Shah; Jianxin Lin
Journal:  Stat Med       Date:  2013-04-12       Impact factor: 2.373

9.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04

10.  Statistical approaches to identify subgroups in meta-analysis of individual participant data: a simulation study.

Authors:  Michail Belias; Maroeska M Rovers; Johannes B Reitsma; Thomas P A Debray; Joanna IntHout
Journal:  BMC Med Res Methodol       Date:  2019-09-02       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.